^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)

    i
    Other names: NTRK2, TRKB, Neurotrophic tyrosine kinase, receptor, type 2
    6d
    Three novel concomitant NTRK2 fusions in medullary thyroid carcinoma with diagnostic implications. (PubMed, Discov Oncol)
    Tumors harboring these fusions respond dramatically to TRK inhibitors (e.g., larotrectinib, entrectinib, and repotrectinib), which selectively target the constitutively active fusion protein. Conclusively, this first report of three novel NTRK2 fusion transcript variants co-occurrence in an MTC patient expands the known spectrum of translocation partners in NTRK2 rearrangements. Prospective validation of their impact on TRK-targeted therapy efficacy and disease prognosis requires long-term follow-up.
    Journal
    |
    NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • Augtyro (repotrectinib)
    7d
    Repetitive Magnetic Stimulation Modulates the Gene Expression of Neurotrophins and their Receptors in Neuroblastoma Cells. (PubMed, Anticancer Res)
    rMS did not affect cell viability or death in these in vitro models. In the 75- and 300-sec groups, increased neurotrophic gene expression was observed immediately after rMS exposure in both neuroblastoma cell lines, subsequently reducing after 24 h. These data demonstrate molecular effects that are specific to exposure time and cell line, validating this specific in vitro rMS prototype and stimulation protocol.
    Journal
    |
    NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • BDNF (Brain Derived Neurotrophic Factor)
    7d
    Retrospective Comparison of Operational Metrics Across Diagnostic Approaches for Molecular Testing in Lung and Colon Cancers in a Community-Based Setting. (PubMed, Arch Pathol Lab Med)
    OFA balances TAT, QNS, and detection, whereas SO-NGS offers comprehensive detection with longer TAT and higher QNS. An optimized assay combining SGP's speed, OFA's reliability, and SO-NGS's comprehensiveness could improve outcomes.
    Retrospective data • Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • TYK2 (Tyrosine Kinase 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    KRAS G12C • HER-2 amplification • HER-2 mutation • MET exon 14 mutation • KRAS G12 • KRAS amplification • NRAS G12
    |
    Oncomine Focus Assay
    8d
    Do targeted NGS panels include NSCLC guideline-recommended biomarkers? (PubMed, Am J Manag Care)
    Of 77 unique panels evaluated, only 5 captured all recommended biomarkers for mNSCLC. Ensuring targeted panels assess all relevant biomarkers is crucial for optimal patient treatment.
    Journal • Next-generation sequencing
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    MET amplification • MET exon 14 mutation • NTRK fusion
    8d
    Atlas-Guided Nanocarrier Strategies Targeting Spatial NTRK2/MAPK Signaling in EGFR-TKI-Resistant Niches of Esophageal Squamous Cell Carcinoma. (PubMed, Pharmaceutics)
    This work provides a conceptual and technological roadmap for overcoming EGFR-TKI resistance in ESCC. Atlas-guided nanocarrier systems offer a promising avenue for spatially targeted and feedback-responsive therapy, highlighting the role of pharmaceutics in advancing precision oncology.
    Review • Journal
    |
    NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    9d
    Corticosteroids for Managing TRK Inhibitor Withdrawal Pain: A Report on Two Cases. (PubMed, Curr Oncol)
    Inhibitors such as larotrectinib, entrectinib and repotrectinib are used when cancer cells harbor NTRK1, NTRK2 or NTRK3 fusion...Short courses of prednisone for the former and dexamethasone for the latter were initiated after failure of standard analgesia... For patients experiencing TRK inhibitor withdrawal pain, especially when tapering down the inhibitor is not an available strategy, a short course of corticosteroids can provide lasting relief. These cases emphasize the importance of better understanding the mechanism underlying the relationship between NRTK, NGF and nociception.
    Journal
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK positive • NTRK fusion
    |
    Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • Augtyro (repotrectinib) • prednisone • dexamethasone
    9d
    TRKB-based signature identifies high-risk squamous cell carcinoma cases and TRKB blockade reprograms tumor and stromal cells toward suppressive phenotypes. (PubMed, J Biomed Sci)
    Our findings provide a basis for improved high-risk patient stratification by highlighting a TrkB-based signature and generating prototype predictive models. Furthermore, they offer promising therapeutic avenues for developing combined targeted interventions to overcome resistance in high-risk patients.
    Journal
    |
    TP53 (Tumor protein P53) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NOTCH1 (Notch 1) • IL6 (Interleukin 6) • CDH1 (Cadherin 1) • YAP1 (Yes associated protein 1) • TYK2 (Tyrosine Kinase 2) • TP63 (Tumor protein 63) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    TP53 mutation
    14d
    Larotrectinib in Patients With Tumors With NTRK Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E. (PubMed, JCO Precis Oncol)
    NCI-MATCH subprotocol Z1E demonstrates that larotrectinib offers clinically significant benefit with marked ORR across NTRK fusion-positive tumors with no clinically significant toxicities. These findings support the rationale for the US Food and Drug Administration's tissue-agnostic approval of larotrectinib for NTRK fusion-positive tumors. Our findings demonstrate the necessity of including NTRK1, NTRK2, and NTRK3 within comprehensive molecular assays of cancer to navigate patients to an easily administered and highly effective therapy.
    Journal
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK positive • NTRK fusion
    |
    Vitrakvi (larotrectinib)
    17d
    BT8009-202: Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer (2025-521115-40-00)
    P1/2, N=28, Recruiting, Bicycletx Limited
    New P1/2 trial
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    zelenectide pevedotin (BT8009)
    21d
    Pediatric NTRK-rearranged gliomas: A clinicopathological and molecular analysis of six cases. (PubMed, Pathol Res Pract)
    This study expands the clinicopathological and molecular spectrum of pediatric NTRK-rearranged gliomas, including rare entities and complex fusion patterns, and supports routine NTRK testing in pediatric gliomas irrespective of histological grade.
    Journal
    |
    TP53 (Tumor protein P53) • ABL1 (ABL proto-oncogene 1) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ETV6 (ETS Variant Transcription Factor 6) • MSH2 (MutS Homolog 2) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • CHEK1 (Checkpoint kinase 1) • NTRK (Neurotrophic receptor tyrosine kinase) • ARHGEF11 (Rho Guanine Nucleotide Exchange Factor 11)
    |
    NTRK fusion
    23d
    Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC (clinicaltrials.gov)
    P2, N=46, Not yet recruiting, Massachusetts General Hospital
    New P2 trial • IO biomarker
    |
    ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • RET fusion • ALK fusion • ROS1 fusion
    |
    carboplatin • pemetrexed • Yidafan (ivonescimab)
    26d
    Lactoferrin inhibits anoikis-resistance and metastasis of nasopharyngeal carcinoma cells via the AKT signaling pathway. (PubMed, Int J Clin Exp Pathol)
    Our study revealed that LTF inhibits anoikis-resistance and metastasis of NPC cells via the AKT signaling pathway.
    Journal
    |
    NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CDH1 (Cadherin 1) • VIM (Vimentin) • MMP9 (Matrix metallopeptidase 9)